Renaissance Capital logo

Pfenex Priced, NYSE American: PFNX

Developing a biosimilar version of Roche's Lucentis treatment for wet AMD.

Industry: Health Care

First Day Return: -11.7%

Industry: Health Care

Developing a biosimilar version of Roche's Lucentis treatment for wet AMD.
more less

Pfenex (PFNX) Performance